🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

DexCom Q3 earnings beat estimates, but stock tumbles 16% on weak growth

Published 10/24/2024, 04:08 PM
© Reuters.
DXCM
-

DexCom (NASDAQ:DXCM) reported third-quarter earnings that surpassed analyst expectations, but the company's stock plummeted 16% as revenue growth slowed significantly.

The continuous glucose monitoring systems maker posted adjusted earnings per share of $0.45, beating the analyst consensus of $0.43. Revenue for the quarter came in at $994.2 million, slightly above the estimated $990.44 million and up 2% YoY.

Despite the earnings beat, DexCom's revenue growth rate of 2% marked a sharp deceleration from previous quarters, likely contributing to the negative market reaction. U.S. revenue declined 2% YoY, while international revenue grew 12% on a reported basis.

"Dexcom's third quarter results were in line with our expectations as our team responded quickly to the business dynamics that emerged earlier this year," said Kevin Sayer, DexCom's chairman, president and CEO.

The company maintained its full-year 2024 revenue guidance of $4.00-4.05 billion, representing 11-13% organic growth. This outlook is in line with the analyst consensus of $4.01 billion.

DexCom's GAAP operating income fell to $152.0 million or 15.3% of revenue, a decrease of 580 basis points compared to the same quarter last year. Non-GAAP operating income was $212.0 million or 21.3% of revenue, down 320 basis points YoY.

The company announced the launch of Stelo, an over-the-counter glucose biosensor for adults with prediabetes and type 2 diabetes not on insulin therapy. DexCom also expanded its international presence with product launches in Australia and France.

Additionally, DexCom revealed that Teri Lawver, Executive Vice President and Chief Commercial Officer, will retire at the end of the year. CEO Kevin Sayer will assume leadership of the commercial organization during the search for a new chief commercial officer.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.